Ignite Creation Date:
2024-05-05 @ 4:56 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00353379
Status:
TERMINATED
Last Update Posted:
2017-02-10
First Post:
2006-07-14
Brief Title:
Pharmacology of Cognition in Schizotypal Personality Disorder
Sponsor:
Icahn School of Medicine at Mount Sinai
Organization:
Icahn School of Medicine at Mount Sinai
Study Overview
Official Title:
Pharmacology of Cognition in Schizotypal Personality Disorder Guanfacine for Cognitive Symptoms in Schizotypal Personality Disorder
Status:
TERMINATED
Status Verified Date:
2017-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
low enrollment
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will determine the effectiveness of guanfacine in improving cognitive and functional impairments in schizotypal personality disorder
Detailed Description:
Schizotypal personality disorder is a psychiatric condition that is characterized by deficiencies in interpersonal relationships and disturbances in thought patterns appearance and behavior This disorder is different from schizophrenia While some of the symptoms of the two disorders are similar such as the tendency to have unusual beliefs and behaviors people with schizotypal personality disorder do not experience hallucinations and are not significantly disconnected from reality both of which are signature symptoms of schizophrenia Guanfacine is a drug that is often used to treat high blood pressure and attention deficit hyperactivity disorder There is evidence that guanfacine enhances cognition and diminishes impulsivity This study will determine the effectiveness of guanfacine in improving symptoms of schizotypal personality disorder
Participants in this 6-week double-blind study will be randomly assigned to receive either guanfacine or placebo Participants receiving guanfacine will remain on the drug for the duration of the study The other participants will receive placebo for the duration of the study Guanfacine dosages will not exceed 2 mg per day All participants will report to the study site weekly for assessments of vital signs study compliance medication side effects and psychological symptoms Additional cognitive testing will be performed at week 6 Upon study completion patients will return for a follow-up assessment
Participants in this 6-week double-blind study will be randomly assigned to receive either guanfacine or placebo Participants receiving guanfacine will remain on the drug for the duration of the study The other participants will receive placebo for the duration of the study Guanfacine dosages will not exceed 2 mg per day All participants will report to the study site weekly for assessments of vital signs study compliance medication side effects and psychological symptoms Additional cognitive testing will be performed at week 6 Upon study completion patients will return for a follow-up assessment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| DATR A3-NSS | US NIH GrantContract | None | httpsreporternihgovquickSearchR01MH056140 |
| R01MH056140 | NIH | None | None |